Details

Autor(en) / Beteiligte

• Mahoney, John J
• Maguire, Patricia
• Ellison, John M
• Cariski, Alan T
• Cembrowski, George S
• Tran, Dave
• Slater-MacLean, Linda
• Chin, Wu Dat
• Gibney, Noel
• Jacka, Michael J

Titel

Response to Cembrowski et al. regarding "Could Susceptibility to Low Hematocrit Interference Have Compromised the Results of the NICE-SUGAR Trial?"/In Reply

Ist Teil von

• Clinical chemistry (Baltimore, Md.), 2010-10, Vol.56 (10), p.1643

Ort / Verlag

Washington: Oxford University Press

Erscheinungsjahr

2010

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• [...] SureStep®Flexx® data points were included only when the sample was collected within 15 min of the blood gas analyzer sample. [...] the authors concede that the NICE-SUGAR protocol contained many factors that might explain the increased prevalence of hypoglycemic events in the intensively treated group. A more cogent argument would have included details of hypoglycemic events along with the actual bias associated with the glucosemeasuring device and the patient's hematocrit. Because these data are not presented, the premise that a hematocrit effect, or device performance, caused hypoglycemic events in the NICE-SUGAR study is unfounded.